Evidence map›Paper›PMID 37705244›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2023

Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD.

Toru Uchiyama, Toshinao Kawai, Kazuhiko Nakabayashi, Yumiko Nakazawa, Fumihiro Goto, Kohji Okamura, Toyoki Nishimura, Koji Kato, Nobuyuki Watanabe, Akane Miura and 12 more

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Clinical hematopoietic stem cell-based gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Myelodysplasia and transgene inactivation in X-CGD-γ retroviral gene therapy: The usual suspects and new players.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Toru UchiyamaDepartment of Human Genetics, National Center for Child Health and Development, Tokyo, Japan. Electronic address: uchiyama-t@ncchd.go.jp.
Toshinao KawaiDivision of Immunology, National Center for Child Health and Development, Tokyo, Japan.
Kazuhiko NakabayashiDepartment of Maternal-Fetal Biology, National Center for Child Health and Development, Tokyo, Japan.
Yumiko NakazawaDivision of Immunology, National Center for Child Health and Development, Tokyo, Japan.
Fumihiro GotoDivision of Immunology, National Center for Child Health and Development, Tokyo, Japan.
Kohji OkamuraDepartment of Systems BioMedicine, National Center for Child Health and Development, Tokyo, Japan.
Toyoki NishimuraDivision of Pediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Koji KatoDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Nobuyuki WatanabeDepartment of Human Genetics, National Center for Child Health and Development, Tokyo, Japan.
Akane MiuraDepartment of Human Genetics, National Center for Child Health and Development, Tokyo, Japan.
Toru YasudaDepartment of Human Genetics, National Center for Child Health and Development, Tokyo, Japan.
Yukiko AndoDepartment of Human Genetics, National Center for Child Health and Development, Tokyo, Japan.
Tomoko MinegishiDepartment of Human Genetics, National Center for Child Health and Development, Tokyo, Japan.
Kaori EdasawaDepartment of Human Genetics, National Center for Child Health and Development, Tokyo, Japan.
Marika ShimuraDepartment of Human Genetics, National Center for Child Health and Development, Tokyo, Japan.
Yumi AkibaDepartment of Human Genetics, National Center for Child Health and Development, Tokyo, Japan.
Aiko Sato-OtsuboDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Pediatric Hematology and Oncology, National Center for Child Health and Development, Tokyo, Japan.
Tomoyuki MizukamiDepartment of Pediatrics, NHO Kumamoto Medical Center, Kumamoto, Japan.
Motohiro KatoDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Pediatric Hematology and Oncology, National Center for Child Health and Development, Tokyo, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Hiroyuki NunoiDivision of Pediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Masafumi OnoderaDepartment of Human Genetics, National Center for Child Health and Development, Tokyo, Japan.
National Center For Child Health and Development · JPKyushu University · JPUniversity of Miyazaki · JPKumamoto Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stem cell gene therapy using the MFGS-gp91

Indexed as

Granulomatous Disease, ChronicMyelodysplastic SyndromesAdultClonal HematopoiesisGenetic TherapyHumansNADPH Oxidase 2NADPH OxidasesRetroviridaeCYBB protein, humanNADPH Oxidase 2NADPH OxidasesAPOBEC3CGDhypermutationinsertional mutagenesisMECOMretroviral vectorWT1

Identifiers

PMID37705244
PMCPMC10727956
OpenAlexW4386629622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.